Table 1.
Monoclonal antibody characterization
| mAb/ polyclonal sera | M/H/C | Binding | Neutralization (W/M/S) | Binding region | Binding DENV serotypes | Ref | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| DV1 | DV2 | DV3 | DV4 | ZIKV | ||||||
| 4G2 | M | F-CR | W | DII FL | ++ | ++ | +++ | +++ | +++ | [26] |
| 1F4 | H | DV1 | DV1:S | DI/DII hinge Q | +++ | – | – | – | – | [7] |
| 12C1.5 | M | D-CR | DV:S | DIII | ++ | ++ | +++ | ++ | – | [27] |
| 1C19 | H | D-CR | DV:M | DII FL/BC | ++ | ++ | ++ | + | ++ | [28] |
| 2D22 | H | DV2 | DV2:S ZIKV:W | DII/DIII Q | – | ++ | – | – | – | [5, 29] |
| 5J7 | H | DV3 | DV3:S | DI/DII Q | – | – | +++ | – | – | [23] |
| 5H2 | C | DV4 | DV4:S | DI Q | – | – | – | + | – | [24] |
| 1 M7 | H | F-CR | M | DII FL | +++ | ++ | +++ | +++ | +++ | [30] |
| A11 (EDE2) | H | F-CR | DV:S ZIKV:W | DI/DII/DIII Q | +++ | +++ | +++ | +++ | + | [31] |
| B7 (EDE2) | H | F-CR | DV:S ZIKV:W | DI/DII/DIII Q | +++ | +++ | +++ | +++ | + | [31] |
| C8 (EDE1) | H | F-CR | DV:S ZIKV:S | DII/DIII Q | +++ | +++ | +++ | +++ | ++ | [31] |
| C10 (EDE1) | H | F-CR | DV:S ZIKV:S | DII/DIII Q | +++ | +++ | +++ | +++ | ++ | [31] |
| 3H5 | M | DV2 | DV2:S | DIII LR | – | +++ | – | – | – | [32] |
| 8A1 | M | DV3 | DV3:S | DIII | – | – | +++ | – | – | [33] |
| DV4 126 | H | DV4 | DV4:S | DI/DII hinge Q | – | – | – | +++ | – | [8] |
| DV4 131 | H | DV4 | DV4:S | DI/DII hinge Q | – | – | – | +++ | – | [8] |
| DV4 141 | H | DV4 | None | DIII | – | – | – | +++ | – | [8] |
| DT000 | H | D-CR | DV:S ZIKV:W | +++ | +++ | +++ | ++ | – | [21] | |
Dengue specific monoclonal antibodies. A panel of well-defined mouse, human or chimpanzee (M/H/C) derived Mabs were used to characterize sRecE epitopes. Flavivirus cross reactive (F-CR), dengue cross reactive (D-CR), weakly, moderately or strong (W/M/S) neutralizing, E-domain I, II, III (DI, DII, DIII), fusion loop (FL), BC-loop (BC), lateral ridge (LR), quaternary (Q)